EssilorLuxottica Extends Agreement with Dolce&Gabbana Until 2050
EssilorLuxottica and Dolce&Gabbana have announced the extension of their licensing agreement until 2050. This agreement covers the design, production, and global distribution of frames for prescription glasses and sunglasses under the Dolce&Gabbana brand.
EssilorLuxottica and Dolce&Gabbana are reinforcing their partnership by extending their licensing agreement until 2050. This agreement encompasses the design, production, and worldwide distribution of frames for prescription glasses and sunglasses under the Dolce&Gabbana brand. According to Francesco Milleri, CEO of EssilorLuxottica, this 25-year extension reflects the evolution of the collaboration towards a long-term oriented model, enabling deep integration of values, strategic vision, and product culture.
A Partnership Built on Mutual Trust
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
The partnership between EssilorLuxottica and Dolce&Gabbana has been developing since 2004, combining commercial performance and creative vision. Alfonso Dolce, CEO of Dolce&Gabbana, stated that the reinforcement of this long-term partnership is a testament to the mutual trust between the two companies in future opportunities. EssilorLuxottica is credited for its expertise in eyewear manufacturing, product quality, the breadth of its global distribution network, and commitment to technological innovation.
C’est une année historique pour EssilorLuxottica : pour la première fois depuis l’origine du Groupe, notre chiffre d’affaires a enregistré une croissance à deux chiffres à taux de change constant, après un quatrième trimestre affichant une croissance record de 18,4 %.
Résultats annuels 2025 marquent une croissance du chiffre d’affaires de 11,2% et une marge opérationnelle ajustée de 15,7%; le cash-flow libre atteint 2,8 milliards d'euros; dividende proposé de 4,00 euros; acquisitions et initiatives med-tech renforcent le positionnement.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
